Incyte Corp (INCY.OQ)
INCY.OQ on NASDAQ Stock Exchange Global Select Market
24.99USD
1 Aug 2013
24.99USD
1 Aug 2013
Price Change (% chg)
$1.58 (+6.75%)
$1.58 (+6.75%)
Prev Close
$23.41
$23.41
Open
$23.59
$23.59
Day's High
$24.99
$24.99
Day's Low
$23.59
$23.59
Volume
56,272
56,272
Avg. Vol
312,570
312,570
52-wk High
$26.15
$26.15
52-wk Low
$15.43
$15.43
About
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the... (more)
Overall
| Beta: | 2.14 |
| Market Cap (Mil.): | $3,177.89 |
| Shares Outstanding (Mil.): | 135.75 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| INCY.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.12 | -- | -- |
| ROI: | -8.08 | -2.58 | 18.76 |
| ROE: | -- | -2.66 | 19.59 |
Lilly says arthritis pill effective in mid-stage study
- Eli Lilly and Co and Incyte Corp said their experimental drug was effective in reducing painful symptoms associated with rheumatoid arthritis after 52 weeks of treatment.
Lilly says arthritis pill effective in mid-stage study
June 13 - Eli Lilly and Co and Incyte Corp said their experimental drug was effective in reducing painful symptoms associated with rheumatoid arthritis after 52 weeks of treatment.
Incyte shares fall on fears over Jakafi-related infection
March 18 - Incyte Corp said a 75-year-old male patient taking its lead drug to treat a rare bone marrow disease developed a brain infection but that it was not immediately clear whether the drug, ruxolitinib, caused it.
Competitors
| Price | Change | |
|---|---|---|
| Amgen, Inc. (AMGN.OQ) | $108.92 | +0.63 |
| Abbott Laboratories (ABT.N) | $36.96 | +0.33 |
| Array Biopharma Inc (ARRY.OQ) | $6.91 | +0.25 |
| Biogen Idec Inc (BIIB.OQ) | $220.41 | +2.28 |
| Pfizer Inc. (PFE.N) | $29.29 | +0.06 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$495.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

